DiaMedica Therapeutics Inc. (DMAC) Current Ratio
- Current ratio · latest quarter: Value 6.72×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 6.72× | Current assets / current liabilities. $44.31M ÷ $6.59M ≈ 6.72× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 44.31M USD | Assets, Current |
| Current obligations | 6.59M USD | Liabilities, Current |
| Cash and equivalents | 5.13M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 38.38M USD | Marketable Securities, Current |
| Customer receivables | 244.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 2.81M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $44.31M | $6.59M | $5.13M | $38.38M | $244.00K | (m) | $2.81M | (m) | 6.72× |
| 2026-03-31 | $52.36M | $5.75M | $4.87M | $46.46M | $301.00K | (m) | $3.29M | (m) | 9.11× |
| 2025-12-31 | $60.63M | $5.13M | $15.65M | $44.24M | $258.00K | (m) | $1.48M | (m) | 11.81× |
| 2025-09-30 | $56.22M | $5.27M | $3.33M | $51.99M | $260.00K | (m) | $1.92M | (m) | 10.67× |
| 2025-06-30 | $31.08M | $4.12M | $4.11M | $25.93M | $161.00K | (m) | $1.26M | (m) | 7.55× |
| 2025-03-31 | $37.42M | $4.67M | $2.59M | $33.73M | $253.00K | (m) | $1.51M | (m) | 8.02× |
| 2024-12-31 | $44.61M | $5.39M | $3.02M | $41.12M | $236.00K | (m) | $940.00K | (m) | 8.28× |
| 2024-09-30 | $50.77M | $4.30M | $4.13M | $46.06M | $290.00K | (m) | $1.17M | (m) | 11.81× |
| 2024-06-30 | $55.01M | $3.09M | $14.07M | $39.99M | $391.00K | (m) | $759.00K | (m) | 17.82× |
| 2024-03-31 | $47.48M | $2.62M | $2.10M | $44.42M | $399.00K | (m) | $716.00K | (m) | 18.14× |
| 2023-12-31 | $53.67M | $2.79M | $4.54M | $48.35M | $369.00K | (m) | $926.00K | (m) | 19.27× |
| 2023-09-30 | $47.89M | $2.17M | $2.23M | $44.23M | $310.00K | (m) | $863.00K | (m) | 22.07× |
| 2023-06-30 | $41.23M | $1.95M | $5.84M | $34.53M | $188.00K | (m) | $856.00K | (m) | 21.19× |
| 2023-03-31 | $29.67M | $2.81M | $2.15M | $26.51M | $57.00K | (m) | $1.78M | (m) | 10.55× |
| 2022-12-31 | $33.84M | $2.17M | $4.73M | $28.77M | $82.00K | (m) | $734.00K | (m) | 15.61× |
| 2022-09-30 | $36.49M | $1.54M | $2.77M | $33.31M | $75.00K | (m) | $864.00K | (m) | 23.66× |
| 2022-06-30 | $39.17M | $1.54M | $3.06M | $35.38M | $88.00K | (m) | $624.00K | (m) | 25.50× |
| 2022-03-31 | $42.11M | $1.43M | $3.03M | $38.02M | $168.00K | (m) | $433.00K | (m) | 29.37× |
| 2021-12-31 | $45.44M | $1.52M | $4.71M | $40.41M | $130.00K | (m) | $509.00K | (m) | 29.82× |
| 2021-09-30 | $48.54M | $1.62M | $16.22M | $31.88M | $104.00K | (m) | $699.00K | (m) | 29.89× |
| 2021-06-30 | $21.63M | $1.44M | $2.23M | $19.07M | $16.00K | (m) | $239.00K | (m) | 15.02× |
| 2021-03-31 | $24.20M | $1.18M | $3.33M | $20.07M | $337.00K | (m) | $689.00K | (m) | 20.54× |
| 2020-12-31 | $27.92M | $2.03M | $7.41M | $20.10M | $340.00K | (m) | $1.10M | (m) | 13.77× |
| 2020-09-30 | $31.11M | $1.44M | $9.80M | $20.83M | $335.00K | (m) | $720.00K | (m) | 21.56× |
| 2020-06-30 | $12.40M | $1.22M | $4.96M | $6.84M | $319.00K | (m) | $552.00K | (m) | 10.19× |
| 2020-03-31 | $14.16M | $935.00K | $3.30M | $9.35M | $985.00K | (m) | $444.00K | (m) | 15.15× |
| 2019-12-31 | $8.84M | $1.32M | $3.88M | $4.00M | $823.00K | (m) | $182.00K | (m) | 6.70× |
| 2019-09-30 | $10.81M | $1.21M | $4.74M | $5.00M | $664.00K | (m) | $312.00K | (m) | 8.97× |
| 2019-06-30 | $12.28M | $947.00K | $2.97M | $7.99M | $1.11M | (m) | $262.00K | (m) | 12.96× |
| 2019-03-31 | $14.94M | $1.43M | $2.76M | $10.96M | $929.00K | (m) | $685.00K | (m) | 10.49× |
| 2018-12-31 | $17.97M | $1.30M | $16.82M | (m) | $780.00K | (m) | $483.00K | (m) | 13.87× |
| 2017-12-31 | $1.49M | $1.00M | (m) | (m) | $80.00K | (m) | (m) | (m) | 1.49× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |